UPDATE: SunTrust Initiates Coverage on Myriad Genetics on Pricing Risk

In a report published Friday, SunTrust Robinson Humphrey analyst Amit Hazan initiated coverage on Myriad Genetics MYGN with a Reduce rating and $17.00 price target. In the report, SunTrust Robinson Humphrey noted, “Our due diligence leads us to believe that the most imminent threat from new competitors for BRACAnalysis is not market share loss, but pricing pressures. We believe private insurer re-evaluation is currently ongoing on a broad scale and could realistically drive the price down by as much as 50% over the next two years. The Street's sales growth expectations for both FY14 and FY15 imply little to no pricing pressure, and we view that as a significant risk. The recent CMS reduction of COLARIS reimbursement by 46% is a good proxy here.” Myriad Genetics closed on Thursday at $24.57.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorInitiationAnalyst RatingsAmit HazanSunTrust Robinson Humphrey
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!